US OptionsDetailed Quotes
AUTL250117C2500
- 0.19
- -0.01-5.00%
15min DelayClose Dec 27 16:00 ET
0.21High0.19Low
0.21Open0.20Pre Close73 Volume402 Open Interest2.50Strike Price1.50KTurnover799.48%IV19.03%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier20DDays to Expiry0.19Extrinsic Value100Contract SizeAmericanOptions Type0.8158Delta0.0619Gamma1.56Leverage Ratio-0.0284Theta0.0002Rho1.27Eff Leverage0.0014Vega
Autolus Therapeutics Stock Discussion
Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024
Autolus Therapeutics (NASDAQ: AUTL)presented clinical data updates at ASH 2024, featuring one oral and three poster presentations about obecabtagene autoleucel (obe-cel) for relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL).
The FELIX trial demonstrated that obe-cel treatment achieved deep molecular remission in 84% of responde...
4 MINUTES AGO, 7:30 PM EST
VIA GLOBENEWSWIRE
ya I'm getting in here
Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obecabtagene autoleucel – obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)
• AUCATZYL is the first CAR T therapy approved by the FDA with no requirement for a REMS program (Risk Evaluation Mitigation Strategy)
• Approval based on FELIX clinical trial of obe-cel in adult patients with r/r B-ALL
• Conference call to be held on November 11 at 08:30 am EST/13:3...
Abeona Therapeutics ( $Abeona Therapeutics (ABEO.US)$ )
Asset: Pz-cel (prademagene zamikeracel)
PDUFA Date: May 25, 2024
Indication: Recessive dystrophic epidermolysis bullosa (RDEB)
Technology: Autologous cell therapy, treatment uses gene transfer to deliver COL7A1 genes into an RDEB patient’s own skin cells then transplanting them back to the patient.
Rocket Pharmaceuticals ( $Rocket Pharmaceuticals (RCKT.US)$ ) ...
No comment yet